Attovia Therapeutics, Inc. Payments of Stock Issuance Costs
Attovia Therapeutics, Inc. (ATTO) reported Payments of Stock Issuance Costs of $1.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-09-02
- 2026-06-30: Payments of Stock Issuance Costs 6 month $1.84M.
- 2025-06-30: Payments of Stock Issuance Costs 6 month $371.00K.
| Period end | Payments of Stock Issuance Costs 6 month |
|---|---|
| 2026-06-30 | $1.84M 10-Q · filed 2026-09-02 |
| 2025-06-30 | $371.00K 10-Q · filed 2026-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |